135 related articles for article (PubMed ID: 6104914)
1. Central monoamine synapses as sites of action for ergot drugs.
Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic treatment with l-sulpiride and haloperidol on central monoaminergic mechanisms.
Fuxe K; Ogren SO; Hall H; Agnati LF; Andersson K; Köhler C; Schwarcz R
Adv Biochem Psychopharmacol; 1980; 24():193-206. PubMed ID: 6967676
[TBL] [Abstract][Full Text] [Related]
3. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of neurotransmitter receptor binding by ergot derivatives.
Hruska RE; Silbergeld EK
J Neurosci Res; 1981; 6(1):1-11. PubMed ID: 6111611
[TBL] [Abstract][Full Text] [Related]
5. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
[TBL] [Abstract][Full Text] [Related]
6. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
7. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
9. Action of dopamine receptor agonists in forebrain and hypothalamus: rotational behavior, ovulation, and dopamine turnover.
Fuxe K; Agnati LF; Corrodi H; Everitt BJ; Hökfelt T; Löfström A; Ungerstedt U
Adv Neurol; 1975; 9():223-42. PubMed ID: 1146654
[TBL] [Abstract][Full Text] [Related]
10. Brain neurotransmitter receptor binding and nootropic studies on Indian Hypericum perforatum Linn.
Kumar V; Khanna VK; Seth PK; Singh PN; Bhattacharya SK
Phytother Res; 2002 May; 16(3):210-6. PubMed ID: 12164263
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
12. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
[TBL] [Abstract][Full Text] [Related]
13. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior.
Broderick PA; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):1037-54. PubMed ID: 14499322
[TBL] [Abstract][Full Text] [Related]
14. Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors.
Tvrdeić A; Pericić D
Coll Antropol; 2003; 27 Suppl 1():175-82. PubMed ID: 12955907
[TBL] [Abstract][Full Text] [Related]
15. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
16. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
Sibley DR; Creese I
Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
[TBL] [Abstract][Full Text] [Related]
17. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
Lew JY; Hata F; Ohashi T; Goldstein M
J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides.
Fuxe K; Agnati LF; Benfenati F; Celani M; Zini I; Zoli M; Mutt V
J Neural Transm Suppl; 1983; 18():165-79. PubMed ID: 6192208
[TBL] [Abstract][Full Text] [Related]
20. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
